Climaval Side Effects
Generic name: estradiol
Medically reviewed by Drugs.com. Last updated on Jan 3, 2024.
Note: This document provides detailed information about Climaval.
For Healthcare Professionals
Applies to estradiol: compounding powder, intramuscular solution, oral tablet, transdermal emulsion, transdermal film extended release, transdermal gel, transdermal spray, vaginal ring Side Effects associated with estradiol. Some dosage forms listed on this page may not apply specifically to the brand name Climaval.
For Healthcare Professionals
Applies to estradiol: compounding powder, intramuscular solution, oral tablet, transdermal emulsion, transdermal film extended release, transdermal gel, transdermal spray, vaginal ring.
Genitourinary
- Very common (10% or more): Breast pain (29%)
- Common (1% to 10%): Vulvovaginal pruritus, leukorrhea, vaginal hemorrhage, vaginal discharge, vaginal discomfort, menopause symptoms, breakthrough bleeding or spotting, dysmenorrhea, breast swelling, menorrhagia, metrorrhagia, endometrial hyperplasia
- Uncommon (0.1% to 1%): Urinary problems
- Rare (less than 0.1%): Galactorrhea
- Postmarketing reports: Vaginal irritation, vaginal pain, genital pruritus, changes in bleeding pattern, pelvic pain, breast tenderness, vaginal ulceration, uterine fibroids[Ref]
Gastrointestinal
- Very common (10% or more): Abdominal pain (16%),
- Common (1% to 10%): Flatulence, nausea, diarrhea
- Uncommon (0.1% to 1%): Vomiting
- Postmarketing reports: Abdominal distension[Ref]
Musculoskeletal
- Very common (10% or more): Back pain (11%), arthralgia (11%)
- Common (1% to 10%): Leg cramps[Ref]
Cardiovascular
- Common (1% to 10%): Varicose veins, cardiac symptoms (e.g. palpitations)
- Uncommon (0.1% to 1%): Hot flush, hypertension, venous thromboembolic disease
- Rare (less than 0.1%): Arterial hypertension
- Postmarketing reports: Deep vein thrombosis, changes in blood pressure[Ref]
Nervous system
- Very common (10% or more): Headache (18%)
- Uncommon (0.1% to 1%): Vertigo, migraine
- Rare (less than 0.1%): Aggravation of epilepsy
- Postmarketing reports: Migraine aggravated, paresthesia, dizziness[Ref]
Oncologic
- Uncommon (0.1% to 1%): Benign breast neoplasm, increased volume of uterine leiomyoma
- Postmarketing reports: Endometrial cancer, breast cancer[Ref]
Other
- Very common (10% or more): Pain (11%)
- Common (1% to 10%): Edema
- Uncommon (0.1% to 1%): Weight increased, asthenia
- Postmarketing reports: Drug ineffectiveness, blood estrogen increase, fatigue, exacerbation of hereditary angioedema[Ref]
Psychiatric
- Common (1% to 10%): Depression
- Uncommon (0.1% to 1%): Sleep disorders, nervousness, mood swings
- Rare (less than 0.1%): Change in libido
- Postmarketing reports: Vaginismus, insomnia, anxiety, irritability[Ref]
Dermatologic
- Common (1% to 10%): Pruritus
- Uncommon (0.1% to 1%): Rash
- Rare (less than 0.1%): Skin discoloration, acne
- Postmarketing reports: Urticaria, erythematous or pruritic rash, alopecia, hyperhidrosis, night sweats, contact dermatitis, eczema[Ref]
Ocular
- Uncommon (0.1% to 1%): Vision abnormal NOS
- Postmarketing reports: Visual disturbances, contact lens intolerance[Ref]
Hepatic
- Rare (less than 0.1%): Liver function tests abnormalities
- Postmarketing reports: Cholestatic jaundice[Ref]
Metabolic
- Rare (less than 0.1%): Glucose intolerance
- Postmarketing reports: Fluid retention[Ref]
Hypersensitivity
- Rare (less than 0.1%): Anaphylactic reaction (with a past history of allergic reaction)
- Postmarketing reports: Anaphylactic reactions, hypersensitivity[Ref]
Immunologic
- Very common (10% or more): Upper respiratory tract infection (17%)
- Common (1% to 10%): Vulvovaginal mycotic infection, pharyngitis, rhinitis, sinusitis, moniliasis genital
- Uncommon (0.1% to 1%): Vaginitis/vaginal candidosis[Ref]
Local
- Common (1% to 10%): Skin irritation (topical gel)
- Postmarketing reports: Application site reaction[Ref]
References
1. Auerbach R, Mittal K, Schwartz PE (1988) "Estrogen and progestin receptors in an ovarian ependymoma." Obstet Gynecol, 71, p. 1043-5
2. Julian TM (1987) "Pseudoincontinence secondary to unopposed estrogen replacement in the surgically castrate premenopausal female." Obstet Gynecol, 70, p. 382-3
3. (2001) "Product Information. Climara (estradiol)." Berlex Laboratories
4. (2001) "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories
5. Nash HA, AlvarezSanchez F, Mishell DR, Fraser IS, Maruo T, Harmon TM (1999) "Estradiol-delivering vaginal rings for hormone replacement therapy." Am J Obstet Gynecol, 181, p. 1400-6
6. Cerner Multum, Inc. "Australian Product Information."
7. (2017) "Product Information. Yuvafem (estradiol topical)." AvKare Inc
8. (2017) "Product Information. Estradiol Vaginal Insert (estradiol topical)." Teva Pharmaceuticals USA
9. Boston Collaborative Drug Surveilance Program (1974) "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med, 290, p. 15-9
10. Crane MG, Harris JJ (1978) "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci, 276, p. 33-55
11. Crane MG, Harris JJ, Winsor W 3d (1971) "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med, 74, p. 13-21
12. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS (1980) "Noncontraceptive estrogens and myocardial infarction in young women." JAMA, 244, p. 339-42
13. Jick H, Dinan B, Rothman KJ (1978) "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA, 239, p. 1407-8
14. Wren BG, Routledge DA (1981) "Blood pressure changes: oestrogens in climacteric women." Med J Aust, 2, p. 528-31
15. Belchetz PE (1994) "Hormonal treatment of postmenopausal women." N Engl J Med, 330, p. 1062-71
16. Stampfer MJ, Colditz GA, Willett WC, et al. (1991) "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med, 325, p. 756-62
17. Barrett-Connor E, Bush TL (1991) "Estrogen and coronary heart disease in women." JAMA, 265, p. 1861-7
18. Grady D, Rubin SM, Petiti DB, et al. (1992) "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med, 117, p. 1016-36
19. Barrett-Connor E, Wingard DL, Criqui MH (1989) "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA, 261, p. 1095-2100
20. Schwartz J, Freeman R, Frishman W (1995) "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol, 35, p. 1-16
21. The Writing Group for the PEPI Trial (1995) "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA, 273, p. 199-208
22. Collins P, Beale CM, Rosano GMC (1996) "Oestrogen as a calcium channel blocker." Eur Heart J, 17 ( Suppl, p. 27-31
23. Bui MN, Arai AE, Hathaway L, Waclawiw MA, Csako G, Cannon RO 3rd (2002) "Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women." Am J Cardiol, 90, p. 82-5
24. Steiger MJ, Quinn NP (1991) "Hormone replacement therapy induced chorea." BMJ, 302, p. 762
25. Cohen L, Coxwell WL, Melchione T, Koltun W, Gibson E, Gupta N, Roberts M (1999) "Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women." Curr Ther Res Clin Exp, 60, p. 534-47
26. Obrink A, Bunne G, Collen J, Tjernberg B (1979) "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand, 58, p. 123
27. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S (1991) "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol, 134, p. 1386-95
28. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S (1991) "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol, 134, p. 1375-85
29. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW (1981) "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol, 114, p. 497-506
30. Thomas DB, Persing JP, Hutchinson WB (1982) "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst, 69, p. 1017-25
31. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R (1979) "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med, 300, p. 9-13
32. Gordon J, Reagan JW, Finkle WD, Ziel HK (1977) "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med, 297, p. 570-1
33. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med, 321, p. 293-7
34. Gray LA Sr, Christopherson WM, Hoover RN (1977) "Estrogens and endometrial carcinoma." Obstet Gynecol, 49, p. 385-9
35. Colditz GA, Hankinson SE, Hunter DJ, et al. (1995) "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med, 332, p. 1589-93
36. The Writing Group for the PEPI Trial (1996) "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA, 275, p. 370-5
37. Gapstur SM, Morrow M, Sellers TA (1999) "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women's health study." JAMA, 281, p. 2091-7
38. Oppenheim G (1984) "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry, 45, p. 34-5
39. Conter RL, Longmire WP Jr (1988) "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg, 207, p. 115-9
40. Aldinger K, Ben-Menachem Y, Whalen G (1977) "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med, 137, p. 357-9
41. Molitch ME, Oill P, Odell WD (1974) "Massive hyperlipemia during estrogen therapy." JAMA, 227, p. 522-5
More about Climaval (estradiol)
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: estrogens
- Breastfeeding
Patient resources
Other brands
Estrace, Estradiol Patch, Dotti, Estrogel, ... +18 more
Professional resources
Other brands
Estrace, Estradiol Patch, Dotti, Estrogel, ... +12 more
Related treatment guides
Further information
Climaval side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.